| |
|
 |
| Teva`s Fast Track to New Cancer Drug
Leverages Bio-Simulation | | Teva will collaborate with Optimata to rescue drug candidates shelved after Phase II or Phase III trials. Optimata’s bio-simulation technology gives new life to discontinued drug candidates by fine-tuning their therapy regimens. ”Because the drug candidates have already been tested in humans, a great deal is already known about them,“ says Pini Orbach, Optimata`s COO.
| | read full article... |
|
|
 |
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
 |
 | European Bio-Clusters Target Israeli Start-Ups
Offer Infrastructure, Networking, Funding | | “Many of the European bio-clusters are now seeking elsewhere for cutting-edge technologies that fit into their areas of clinical or business expertise and are therefore eager to attract Israeli start-ups with matching or complementary technologies,” says Binah Baum, an expert on technology maturation and incubation.
| | read full article... |
|
|
|
|
|
| |
|
|
|
|
|
| |
|
 |
| The White Biotech Revolution
Could Transform Production Methods | | “We are seeing a move from exhaustive synthetic steps to new amazingly efficient and cost-reducing methods in the production of complex pharmaceuticals,” says Martin Austin, Managing Director of TransformRx. Technologies in this field are fragmented but includeforms of mutagenesis, enzyme chimaeras, chemobiocatalysis and in silico enzyme design.
| | read full article... |
|
|
|
|
|
| |
|
 |
| Dr. Irene Fermont:
Vigilant About Risk Management | | Israeli companies need to become more familiar with new European guidelines for risk management and safety if they want to get regulatory approval, says Dr. Irene Fermont, VP of Pharmacovigilance and Risk Management at ADDS (Advanced Drug Development Services).
| | read full article... |
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
| |
|
top of the page
|
|
